Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B K Tang

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Biochemical Pharmacology|October 23, 1998
Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthreneW Li, P A Harper, B K Tang, et al.
Biochemical Pharmacology|April 15, 1987
Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studiesD M Grant, M E Campbell, B K Tang, et al.
Biochemical and Biophysical Research Communications|June 15, 1994
Caffeine biotransformation in human hepatocyte lines derived from normal liver tissueE A Roberts, K N Furuya, B K Tang, et al.
Progress in Clinical and Biological Research|January 1, 1985
Alcohol abuse: detection of acetaldehyde adducts in rat urine following administration of erythrocytes labelled with radioactive acetaldehydeY Israel, B K Tang, J L Tedesco, et al.
Canadian Journal of Physiology and Pharmacology|October 1, 1985
N-Glucosidation of amobarbital in the catG Carro-Ciampi, M Jurima, D Kadar, et al.
Clinical Pharmacology and Therapeutics|December 1, 1979
A method for studying drug metabolism in populations: racial differences in amobarbital metabolismW Kalow, B K Tang, D Kadar, et al.
European Journal of Clinical Pharmacology|October 16, 2001
Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamineS K Sy, B K Tang, A Pastrakuljic, et al.
Clinical Pharmacology and Therapeutics|January 1, 1995
Low CYP1A2 activity in rural Shona children of ZimbabweC M Masimirembwa, M Beke, J A Hasler, et al.
Clinical Pharmacology and Therapeutics|June 1, 1991
Caffeine as a metabolic probe: validation of its use for acetylator phenotypingB K Tang, D Kadar, L Qian, et al.
Clinical Pharmacology and Therapeutics|January 1, 1991
Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactionsM J Rieder, N H Shear, A Kanee, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Biochemical Pharmacology|October 23, 1998
Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthreneW Li, P A Harper, B K Tang, et al.
Biochemical Pharmacology|April 15, 1987
Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studiesD M Grant, M E Campbell, B K Tang, et al.
Biochemical and Biophysical Research Communications|June 15, 1994
Caffeine biotransformation in human hepatocyte lines derived from normal liver tissueE A Roberts, K N Furuya, B K Tang, et al.
Progress in Clinical and Biological Research|January 1, 1985
Alcohol abuse: detection of acetaldehyde adducts in rat urine following administration of erythrocytes labelled with radioactive acetaldehydeY Israel, B K Tang, J L Tedesco, et al.
Canadian Journal of Physiology and Pharmacology|October 1, 1985
N-Glucosidation of amobarbital in the catG Carro-Ciampi, M Jurima, D Kadar, et al.
Clinical Pharmacology and Therapeutics|December 1, 1979
A method for studying drug metabolism in populations: racial differences in amobarbital metabolismW Kalow, B K Tang, D Kadar, et al.
European Journal of Clinical Pharmacology|October 16, 2001
Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamineS K Sy, B K Tang, A Pastrakuljic, et al.
Clinical Pharmacology and Therapeutics|January 1, 1995
Low CYP1A2 activity in rural Shona children of ZimbabweC M Masimirembwa, M Beke, J A Hasler, et al.
Clinical Pharmacology and Therapeutics|June 1, 1991
Caffeine as a metabolic probe: validation of its use for acetylator phenotypingB K Tang, D Kadar, L Qian, et al.
Clinical Pharmacology and Therapeutics|January 1, 1991
Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactionsM J Rieder, N H Shear, A Kanee, et al.
Pageof 7